Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
By
Yvette Florio Lane
Drug Updates
,
FDA Approvals, News & Updates
,
Multiple Myeloma
,
In the Literature
Web Exclusives
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM).
Read More ›
Page 5 of 5
2
3
4
5
